C-R1C8lipid peroxidation, stabilized PUFAs
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Treat dry age-related macular degeneration and geographic atrophy by inhibiting progression of oxidative retinal disease.
Stabilized PUFA therapeutic approach targeting lipid peroxidation in retinal disease.
Pipeline lists RT011 for Dry AMD and geographic atrophy; related oxidative retinal disease patent family published in the US in 2025 and EP in 2024/2025.
Treat Friedreich's ataxia by decreasing lipid peroxidation associated with oxidative damage.
Deuterated linoleic acid therapeutic tested in a double-blind placebo-controlled trial.
2023 publication of an 11-month, 65-subject double-blind placebo-controlled Friedreich's ataxia trial.
RT001 was well tolerated with no related serious adverse events, but showed no significant benefit versus placebo on maximum oxygen consumption or secondary and exploratory outcome measures at the tested doses.
Create first-in-class therapies for degenerative diseases by down-regulating lipid peroxidation and protecting against cellular degeneration.
Use deuterated or otherwise stabilized polyunsaturated fatty acids to reduce hydrogen abstraction and inhibit lipid peroxidation in membranes.
Retrotope lists 'Other stabilized PUFAs' in its pipeline; publications describe D-PUFA protection in lipid bilayers, deuterated arachidonic acid in lung injury models, and deuterated linoleic acid in red blood cell storage models.
Preclinical and model-system results report reduced lipid peroxidation or protection against oxidative damage in lipid bilayers, mouse lung injury, and red blood cell storage models.
Develop RT001 for orphan neurodegenerative indications including INAD, ALS, and PSP by protecting cells against lipid peroxidation-driven degeneration.
Proprietary stabilized PUFA therapeutic intended to down-regulate lipid peroxidation.
Listed in Retrotope's pipeline for INAD, ALS, and PSP.
Develop an additional proprietary Retrotope pipeline therapeutic based on stabilized PUFA chemistry.
Undisclosed stabilized PUFA therapeutic approach.
Listed in Retrotope's pipeline.